This JAMA Insights examines US Food and Drug Administration–approved medications for alcohol use disorder, including the dosing, efficacy, and adverse effects of naltrexone, acamprosate, and disulfiram.
| # | Наименование новости | Тональность | Информативность | Дата публикации |
|---|---|---|---|---|
| 1 | VA launches trial to test GLP-1 medication for alcohol use disorder in veterans | 0 | 4.44 | 30-07-2026 |
| 2 | VA launches trial to test GLP-1 medication for alcohol use disorder in veterans | 0 | 4.44 | 30-07-2026 |
| 3 | Выход есть: как в России борются с алкогольной зависимостью | 0 | 0 | 09-03-2023 |
| 4 | Лечение алкоголизма препаратами: основные группы и реальная эффективность таблеток | 0 | 6.01 | 31-12-2025 |
| 5 | FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose | 0 | 5 | 02-07-2026 |
| 6 | Short-Term and Long-Term Opioid Prescribing by Specialty | 0 | 7 | 07-07-2026 |
| 7 | Unexpected GLP-1 side effect? Studies show the meds may help people with addictions | 0 | 8.21 | 23-08-2026 |
| 8 | Perceived Risk of Fentanyl Use Among US Adolescents | 0 | 5 | 07-07-2026 |
| 9 | Are Physicians Getting the Balance Right on Opioid Prescribing? | 0 | 7.35 | 18-08-2026 |
| 10 | Safety and Mental Health Outcomes of Oregon State-Regulated Psilocybin Services | 0 | 11.79 | 19-08-2026 |